Table 3.
Corticosteroid Use in Patients with mCRPC
| Data set 1 | Data set 2 | |||||
|---|---|---|---|---|---|---|
| Overall mCRPC period (N = 2593) | Secondary hormonal therapy period (N = 1496) | Chemotherapy period (N = 1345) | Overall mCRPC period (N = 626) | Secondary hormonal therapy period (N = 391) | Chemotherapy period (N = 309) | |
| Corticosteroid use | ||||||
| Patients, N (%) | 1903 (73.4) | 939 (62.8) | 1262 (93.8) | 448 (71.6) | 236 (60.4) | 294 (95.1) |
| Drugs dispensed, N | 12.5 ± 13.7 [8.0] | 5.0 ± 5.9 [3.0] | 14.3 ± 14.0 [10.0] | 12.0 ± 10.7 [10.0] | 6.0 ± 7.0 [3.0] | 12.7 ± 10.2 [10.0] |
| Proportion of days covered,a mean ± SD [median] | 35% ± 39 [25] | 36% ± 33 [26] | 37% ± 32 [29] | 38% ± 39 [28] | 39% ± 33 [32] | 41% ± 35 [29] |
| Exposure period, days,b mean ± SD [median] | 540 ± 408 [540] | 406 ± 354 [406] | 419 ± 353 [419] | 536 ± 441 [388] | 414 ± 417 [281] | 383 ± 370 [285] |
| Prednisone use | ||||||
| Patients, N (%) | 1129 (43.5) | 493 (33.0) | 780 (58.0) | 285 (45.5) | 148 (37.9) | 185 (59.9) |
| Daily dose, mg,c mean ± SD [median] | 14.7 ± 15.4 [10.4] | 16.9 ± 20.6 [10.1] | 12.8 ± 10.7 [10.3] | 13.8 ± 10.8 [10.3] | 15.0 ± 13.8 [10.1] | 12.3 ± 7.4 [10.2] |
| Dexamethasone use | ||||||
| Patients, N (%) | 1409 (54.3) | 412 (27.5) | 1180 (87.7) | 347 (55.4) | 110 (28.1) | 283 (91.6) |
| Dexamethasone oral, N (%) | 878 (33.9) | 347 (23.2) | 651 (48.4) | 214 (34.2) | 97 (24.8) | 149 (48.2) |
| Dexamethasone injection, N (%) | 1092 (42.1) | 97 (6.5) | 1039 (77.2) | 274 (43.8) | 25 (6.4) | 262 (84.8) |
a
The proportion of days covered was calculated as the sum of nonoverlapping days of supply in a given period divided by the number of days in that given period.
b
For the subset of patients with corticosteroid use, the exposure period was defined as the number of days of observation for each period.
c
The daily dose was obtained by multiplying the medication strength with the prescribed quantity and then dividing the result by days of supply.
mCRPC indicates metastatic castration-resistant prostate cancer.